Table 1 Characteristics of the patients of the BELFRAIL cohort (N = 567)
Characteristics of the patients | ||
Age (years), median [Q25;Q75] | 84.0 [81.7;86.6] | |
Gender, women, n (%) | 356 (62.8) | |
Resident in a nursing home, n (%) | 57 (10.1) | |
Number of drugs/day, median [Q25;Q75] | 5 [4;7] | |
Geriatric features | ||
Polypharmacy (≥ 5 drugs/day), n (%) | 337 (61) | |
ADL,a median [Q25;Q75] | 25 [21;27] | |
Living alone at home, n (%) | 212 (37.4) | |
Urinary incontinence, n (%) | 126 (22.2) | |
Cognitive impairement, n (%) | 89 (15.7) | |
BMI < 21 kg/m², n (%) | 49 (8.6) | |
MMSE,b median [Q25;Q75] | 28 [25;29] | |
Tinetti score,c median [Q25;Q75] | 27 [24;28] | |
GDS-15,d median [Q25;Q75] | 2 [1;4] | |
CIRS median [Q25;Q75] | 4 [3;5] | |
Most frequent comorbidities | ||
Hypertension, n (%) | 396 (69.8) | |
Osteoarthritis, n (%) | 324 (57.1) | |
Ischemic disease, n (%) | 210 (37.0) | |
Chronic heart failure, n (%) | 166 (29.3) | |
Chronic renal disease (GFR < 50 ml/min), n (%) | 143 (25.2) | |
Osteoporosis, n (%) | 125 (22.0) | |
Diabetes, n (%) | 107 (18.9) | |
Depression, n (%) | 74 (13.1) | |
COPD, n (%) | 65 (11.5) | |
Atrial fibrillation, n (%) | 58 (10.2) | |
Most frequent drugs prescribed, n patients (%) | ||
Antithrombotic agents (B01) | 312 (55.0) | |
Beta-blocking agents (C07) | 238 (42.0) | |
Agents acting on the renin-angiotensin system (C09) | 237 (41.8) | |
Psycholeptics (N05) | 220 (38.8) | |
Diuretics (C03) | 189 (33.3) | |
Lipid Modifying Agents (C10) | 180 (31.7) | |
Drugs for acid related disorders (A02) | 138 (24.3) | |
Calcium Channel Blockers (C08) | 135 (23.8) | |
Psychoanaleptics (N06) | 131 (23.1) | |
Cardiac Therapy (C01) | 115 (20.3) | |
Potentially inappropriate prescribing, n patients (%) | ||
START-PIPs | 336 (59.3) | |
STOPP-PIPs | 232 (40.9) | |
Beers-PIPs | 180 (31.7) |